The REIT Strategy I Would Use To Retire Today
Retirement income requires more than just high yield. REIT funds may not be the best solution. A balanced REIT portfolio can offer income and growth.
ADC - Agree Realty Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$84.06
DETAILS
HIGH:
$91.00
LOW:
$80.00
MEDIAN:
$84.00
CONSENSUS:
$84.06
UPSIDE:
7.84%
Stock News
The 12.9% Monthly Dividend That Quietly Eats Your Portfolio
In the working world, paychecks show up every two weeks. Or at least, every month.
Why Investors Need to Take Advantage of These 2 Finance Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of novel CDH17 targeted ADC, ICP-B208, in China. Developed from InnoCare's in-house ADC platform, ICP-B208 is a novel ADC comprising a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house invented payload via a protease-cleavable linker.
5 Safe Monthly Pay Dividend Stocks Boomers Love in July
Income investors heading into July face a friendlier setup than they did just six weeks ago.
My 5 Greatest REIT Winners Of All Time
Iron Mountain, Tanger, Four Corners, Essential Properties, and Chatham Lodging delivered outsized REIT returns by exploiting price-value gaps during market panics. My disciplined value investing approach focuses on durable business models, strong balance sheets, and buying below intrinsic value, not market timing or headline chasing. IRM and SKT now trade at premium valuations, while EPRT and FCPT remain attractively priced with solid growth and conservative payout ratios; CLDT reached fair value and was exited.
ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on July 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.
Agree Realty Announces Second Quarter 2026 Earnings Release Date and Conference Call Information
Agree Realty Corporation (NYSE: ADC) (the âCompanyâ) today announced that it will release its second quarter 2026 operating results after the market closes
Agree Realty Announces Second Quarter 2026 Earnings Release Date and Conference Call Information
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its second quarter 2026 operating results after the market closes on Thursday, July 30, 2026. A conference call to discuss the Company's operating results is scheduled for Friday, July 31, 2026, at 10:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (833) 461-5787 International (626) 884-3620 .
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (r/r DLBCL). LOTIS-7 trial enrollment is now complete with 100 r/r DLBCL patients dosed at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of 2026 LAUSANNE, Switzerland, June 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a strategic reorganization to focus resources behind key value-driving initiatives in support of the ZYNLONTA® (loncastuximab tesirine-lpyl) franchise. As part of the reorganization, ADC Therapeutics plans to reduce its workforce globally by approximately 17 percent.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma
AU, Switzerland & PRINCETON, N.J.--(BUSINESS WIRE)--Araris Biotech AG, a company advancing a differentiated pipeline of antibody-drug conjugates (“ADCs”) therapies, and Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, both members of the Taiho group, today announced that the first patient has been dosed in a Phase 1 clinical trial of ARC-02, a CD79b-targeted antibody-drug conjugate (ADC) for the treatment of non-Hodgk.
One Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC Therapies
PARIS--(BUSINESS WIRE)-- #adc--One Biosciences receives Paris-Saclay Cancer Cluster (PSCC) BOOST grant to develop first single-cell assay for antibody-drug conjugates therapies.
Why Investors Need to Take Advantage of These 2 Finance Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Agree Realty: This Dividend Compounder Looks Attractive Again
Agree Realty is a high-quality net lease REIT with strong exposure to investment-grade, necessity-based retail tenants and a robust development platform. ADC delivered 7.9% YoY AFFO per share growth in Q1 2026, with a 104% rent recapture rate and active capital recycling supporting bottom-line expansion. I maintain a "buy" rating on ADC, citing its 4.3% yield, conservative 3.2x net debt/EBITDA, and well-covered 70% payout ratio.
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
ZURICH, SWITZERLAND – June 18, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform and its potential to enable more precise and targeted cancer therapies. VERAXA will attend the BIO International Convention in San Diego, Calif.
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.
Price Targets
Jefferies Assumes Agree Realty (ADC) at Buy
$84.00
(was $74.15)
Joe Dickstein
·
Jefferies
Agree Realty price target lowered to $84 from $86 at Barclays
$84.00
(was $75.77)
Richard Hightower
·
Barclays
Agree Realty price target lowered to $80 from $86 at Mizuho
$80.00
(was $76.54)
Mizuho Securities
Agree Realty (ADC) PT Raised to $82 at RBC Capital
$82.00
(was $76.67)
Brad Heffern
·
RBC Capital
Agree Realty price target raised to $81 from $75 at Morgan Stanley
$81.00
(was $78.86)
Ronald Kamdem
·
Morgan Stanley
Agree Realty price target raised to $86 from $81 at Barclays
$86.00
(was $79.56)
Barclays
Agree Realty downgraded to Market Perform from Outperform at BMO Capital
$86.00
(was $78.93)
Eric Borden
·
BMO Capital
Agree Realty price target raised to $91 from $82 at UBS
$91.00
(was $81.06)
UBS
Agree Realty price target raised to $81 from $79 at RBC Capital
$81.00
(was $76.72)
Brad Heffern
·
RBC Capital
Agree Realty price target raised to $84.50 from $83.50 at Stifel
$84.50
(was $76.51)
Stifel Nicolaus
Agree Realty price target lowered to $75 from $77 at Mizuho
$75.00
(was $71.06)
Mizuho Securities
Agree Realty price target lowered to $83 from $85 at Evercore ISI
$83.00
(was $72.24)
Evercore ISI
Agree Realty price target raised to $78 from $77 at Barclays
$78.00
(was $74.15)
Barclays
Agree Realty price target raised to $83 from $81 at Wells Fargo
$83.00
(was $75.11)
John Kilichowski
·
Wells Fargo
Agree Realty (ADC) PT Raised to $83.50 at Stifel
$83.50
(was $75.10)
Simon Yarmak
·
Stifel Nicolaus
Agree Realty price target lowered to $82 from $84 at Truist
$82.00
(was $75.14)
Ki Bin Kim
·
Truist Financial
Agree Realty (ADC) PT Raised to $82 at KeyBanc; 'Investment Output Accelerating'
$82.00
(was $75.14)
Upal Rana
·
KeyBanc
Agree Realty price target raised to $85 from $83 at Evercore ISI
$85.00
(was $73.10)
Evercore ISI
Agree Realty price target raised to $84 from $82 at Truist
$84.00
(was $73.32)
Ki Bin Kim
·
Truist Financial
Agree Realty price target lowered to $80 from $84 at UBS
$80.00
(was $72.23)
Michael Goldsmith
·
UBS